• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Aptorum Group Limited (Amendment)

    6/1/21 4:30:20 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APM alert in real time by email
    SC 13D/A 1 ea142011-sc13da3jurchen_apto.htm AMENDMENT NO. 3 TO SCHEDULE 13D

     

     

    Securities and Exchange Commission, Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    AMENDMENT NO. 3*

     

    APTORUM GROUP LIMITED

    (Name of Issuer)

    Class A Ordinary Shares, $1.00 par value per share
    (Title of Class of Securities)

    G6096M106

    (CUSIP Number)

     

    17 Hanover Square
    London W1S 1BN, the United Kingdom

    Telephone: +44 20 8092 9299

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    May 26, 2021

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13-1(f) or 13d-1(g), check the following box ☐.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP Number: G6096M106

     

    (1) Name of Reporting Persons: Jurchen Investment Corporation (“Jurchen”)
       
      S.S. or I.R.S. Identification Nos. of above persons:
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    (3) SEC Use Only
       
       
    (4) Source of Funds (See Instructions)
       
      OO
    (5) Check if Disclosure of Legal Proceedings is required Pursuant to Items 2(d) or 2(e) ☐
       
       
    (6) Citizenship or Place of Organization:
       
      British Virgin Islands
        (7) Sole Voting Power:
           
    Number of     164,858,303(1)
    Shares   (8) Shared Voting Power:
    Beneficially      
    Owned By     0
    Each   (9) Sole Dispositive Power:
    Reporting      
    Person With    

    164,858,303(1)

        (10) Shared Dispositive Power:
           
            0
    (11) Aggregate Amount Beneficially Owned by Each Reporting Person:
       
     

    164,858,303(1)

    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see Instructions). ☐
       
       
    (13) Percent of Class Represented by Amount in Row (11):
       
     

    69.24% (2)

    (14) Type of Reporting Person (See Instructions):
       
      CO

      

    (1) This includes (i) 3,703,073 Class A Ordinary Shares owned by Jurchen, (ii)16,061,469 Class B Ordinary Shares owned by Jurchen, and (iii) warrants held by Jurchen to purchase 540,540 Class A Ordinary Shares. The Class B Ordinary Shares vote on a one for ten basis; accordingly, Jurchen is entitled to an aggregate of 164,858,303 votes as indicated above. The Reporting Person maintains the right to convert its Class B Ordinary Shares into Class A Ordinary Shares at any time, in its sole discretion, on a one for one basis; following such conversion, the resulting Class A Ordinary Shares will retain the same one for one voting power as all other Class A Ordinary Shares.

     

    (2) Represents the voting power with respect to all of our Class A Ordinary Shares and Class B Ordinary Shares, voting as a single class. Accordingly, the percentage is calculated based on the Issuer's prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) on May 25, 2021, which discloses that there were 11,776,271 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares (such Class B Ordinary Shares entitled to 224,377,540 votes) outstanding immediately before the issuance of the shares triggering the filing of this amendment; therefore, there are 13,164,196 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares (such Class B Ordinary Shares entitled to 224,377,540 votes) outstanding immediately after the offering. In computing the percentage voting power of Jurchen, Ordinary Shares underlying options, warrants or convertible securities held by Jurchen that are exercisable or convertible within 60 days of May 26, 2021 are deemed outstanding.

     

    2

     

     

    CUSIP Number: G6096M106

     

    (1) Name of Reporting Persons: Ian Huen (“Ian”)
       
      S.S. or I.R.S. Identification Nos. of above persons:
    (2) Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    (3) SEC Use Only
       
       
    (4) Source of Funds (See Instructions)
       
      OO
    (5) Check if Disclosure of Legal Proceedings is required Pursuant to Items 2(d) or 2(e) ☐
       
       
    (6) Citizenship or Place of Organization:
       
      Hong Kong
        (7) Sole Voting Power:
           
    Number of    

    164,911,855 (1)

    Shares   (8) Shared Voting Power:
    Beneficially      
    Owned By     0
    Each   (9) Sole Dispositive Power:
    Reporting      
    Person With    

    164,911,855 (1)

        (10) Shared Dispositive Power:
           
            0
    (11) Aggregate Amount Beneficially Owned by Each Reporting Person:
       
     

    164,911,855 (1)

    (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see Instructions). ☐
       
       
    (13) Percent of Class Represented by Amount in Row (11):
       
     

    69.25% (2)

    (14) Type of Reporting Person (See Instructions):
       
      IN

     

    (1) This includes (i) 3,703,073 Class A Ordinary Shares owned by Jurchen, (ii) warrants held by Jurchen to purchase 540,540 Class A Ordinary Shares, (iii) options granted to Ian to purchase 53,552 Class A Ordinary Shares, and (iv)16,061,469 Class B Ordinary Shares owned by Jurchen. Excludes stock options that vest more than 60 days from the date hereof. Jurchen is wholly-owned by Ian and its principal office address is at 17th Floor, Guangdong Investment Tower, 148 Connaught Road Central, Hong Kong located. The Class B Ordinary Shares vote on a one for ten basis; accordingly, Ian is deemed to control an aggregate of 164,858,303 votes through Jurchen and 53,552 votes directly. The Reporting Person maintains the right to convert its Class B Ordinary Shares into Class A Ordinary Shares at any time, in its sole discretion, on a one for one basis; following such conversion, the resulting Class A Ordinary Shares will retain the same one for one voting power as all other Class A Ordinary Shares

     

    (2) Represents the voting power with respect to all of our Class A Ordinary Shares and Class B Ordinary Shares, voting as a single class. Accordingly, the percentage is calculated based on the Issuer's prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) on May 26, 2021, which discloses that there were 11,776,271 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares (such Class B Ordinary Shares entitled to 224,377,540 votes) outstanding immediately before the issuance of the shares triggering the filing of this amendment; therefore, there are 13,164,196 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares (such Class B Ordinary Shares entitled to 224,377,540 votes) outstanding immediately after the offering. In computing the percentage voting power of Ian, Ordinary Shares underlying options, warrants or convertible securities held by Ian that are exercisable or convertible within 60 days of May 26, 2021 are deemed outstanding.

     

    3

     

     

    CUSIP Number: G6096M106

     

    EXPLANATORY NOTE

     

    This Amendment No. 3 to Schedule 13D (this “Schedule 13D/A”) amends and restates the statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on January 3, 2019, as amended by Amendment No. 1, filed with the SEC on May 8, 2019, and Amendment No. 2, filed with the SEC on March 10, 2020 (the “Prior Filings”), with respect to Class A Ordinary Shares, $1.00 par value per share (the “Ordinary Shares”), of Aptorum Group Limited, a Cayman Islands exempted company with limited liability whose principal place of business is in the United Kingdom (the “Issuer” or the “Company”). The Issuer’s principal executive office is located at 17 Hanover Square, London W1S 1BN, the United Kingdom. From and after the date hereof, all references in the Prior Filings to the Prior Filings or terms of similar import shall be deemed to refer to the Prior Filings as amended and supplemented by this Schedule 13D/A.

     

    The purpose of this filing is to revise the beneficial ownership previously reported for Ian Huen and Jurchen Investment Corporation, the Reporting Persons included in the Prior Filing, and to update certain other related information in the Prior Filing.

     

    4

     

     

    CUSIP Number: G6096M106

      

    Item 1. Security and Issuer.

     

    This statement on Schedule 13D (the “Schedule”) relates to the Class A Ordinary Shares, $1.00 par value per share (the “Class A Ordinary Shares”), of Aptorum Group Limited, a Cayman Islands exempted company with limited liability whose principal place of business is in Hong Kong (the “Company”), and is being filed jointly by Jurchen, and Ian (collectively, the “Reporting Persons”). The Company also has Class B Ordinary Shares. The Class B Ordinary Shares vote on a one for ten basis, but the holder can convert into Class A Ordinary Shares at any time, at his/her sole discretion, on a one for one basis.

     

    The Company’s principal offices are located at 17 Hanover Square, London W1S 1BN, United Kingdom. 

     

    Item 2. Identity and Background.

     

      (a) The names of the persons filing this Statement (the “Reporting Persons”) are:

     

      (a) Jurchen; and

     

      (b) Ian.

     

    Ian owns 100% equity interest in Jurchen, which holds 3,703,073 Class A Ordinary Shares, warrants (“Warrants”) to purchase 540,540 Class A Ordinary Shares and 16,061,469 Class B Ordinary Shares of the Company.

     

      (b) The principal business address of each Reporting Person is 17th Floor, Guangdong Investment Tower, 148 Connaught Road Central, Hong Kong.

     

      (c) The principal business of Jurchen is to act as an investment holding company.
         
        The principal business of Ian is Chief Executive Officer and Executive Director of the Company.

     

      (d) During the past five years, none of the Reporting Persons or to the knowledge of the Reporting Persons, the persons identified in this Item 2, have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

      (e) During the past five years, none of the Reporting Persons or to the knowledge of the Reporting Persons, the persons identified in this Item 2, have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was the subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal and state securities laws of findings any violation with respect to such laws.

     

      (f)

    Jurchen is a company incorporated in the British Virgin Islands.

     

    Citizenship of Ian: Hong Kong

     

    5

     

     

    CUSIP Number: G6096M106

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    The aggregate purchase price for the shares currently beneficially owned by Jurchen was $30,307,596. The source of these funds was the working capital of Jurchen.

      

    Item 4. Purpose of Transaction

     

    Jurchen/Ian

     

    The Issuer entered into a Private Placement Shares Purchase Agreement (the “Agreement”) with Jurchen, pursuant to which the Issuer sold 1,387,925 Class A Ordinary Shares at $2.882 per share to Jurchen. The Issuer received aggregate proceeds of USD$4,000,000 from Jurchen pursuant to the Agreement. Following such transfer, Jurchen holds the shares reported herein (3,703,073 Class A Ordinary Shares, warrants to purchase 540,540 Class A Ordinary Shares and 16,061,469 Class B Ordinary Shares) (the “Jurchen Securities”).

     

    The Jurchen Securities owned by Ian and Jurchen have been acquired for investment purposes. Jurchen and/or Ian may make further acquisitions of Class A Ordinary Shares from time to time and, subject to certain restrictions, may dispose of any or all of the Class A Ordinary Shares held by Jurchen and/or Ian at any time depending on an ongoing evaluation of the investment in such securities, prevailing market conditions, other investment opportunities and other factors.

      

    Item 5. Interest in Securities of the Issuer

     

      a. The aggregate number and percentage of the Company’s Class A Ordinary Shares and Class B Ordinary Shares owned by each Reporting Person named herein is calculated based on the Issuer's prospectus filed with the SEC pursuant to Rule 424(b)(5) on May 25, 2020, which discloses that there were 11,776,271 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares (such Class B Ordinary Shares entitled to 224,377,540 votes) outstanding immediately before the issuance of the shares triggering the filing of this amendment; therefore, there are 13,164,196 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares (such Class B Ordinary Shares entitled to 224,377,540 votes) outstanding immediately after the offering.

      

    6

     

     

    CUSIP Number: G6096M106

     

        The beneficial ownership of each of the Reporting Persons is:

      

      i. Jurchen: 164,858,303 (69.24%).

     

      ii. Ian: 164,911,855 (69.25%) 164,858,303 through Jurchen and 53,552 directly.

      

      b. Ian is deemed to have sole voting power, to vote or direct the vote of and to dispose or direct the disposition of the 164,911,855 votes reported herein.

     

      c. There have been no other transactions in the Class A Ordinary Shares effected by the Reporting Persons during the past 60 days.

     

      d. No person other than the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares reported as being beneficially owned (or which may be deemed to be beneficially owned) by the Reporting Persons.

     

      e. Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

     

    The following descriptions are qualified in their entirety by the agreements and instruments included as exhibits to this Schedule.

     

    The Reporting Persons are parties to an agreement with respect to the joint filing of this Schedule and any Schedules hereto. A copy of such agreement is attached as Exhibit 99.1 and is incorporated by reference herein.

     

    On May 26, 2021, the Issuer entered into a Private Placement Shares Purchase Agreement (the “Agreement”) with Jurchen. A copy of such agreement is attached hereto as Exhibit 99.2 and is incorporated by reference herein.

      

    7

     

     

    CUSIP Number: G6096M106

     

    Item 7. Material to Be Filed as Exhibits.

     

    The following are filed herewith as Exhibits to the Schedule 13D:

     

    Exhibit 99.1   Joint Filing Agreement, dated January 3, 2019 (Previously filed as an exhibit to the Reporting Person’s Schedule 13D filed with the SEC on January 3, 2019 and incorporated herein by reference)
         
    Exhibit 99.2   Private Placement Shares Purchase Agreement with Jurchen Investment Corporation (Incorporated by reference to Exhibit 10.1 filed with the Current Report on Form 6-K filed on May 26, 2021)

     

    8

     

     

    CUSIP Number: G6096M106

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: June 1, 2021

         
    Jurchen Investment Corporation  
       
    By: /s/ Ian Huen       
      Name: Ian Huen  
      Title: Director  
         
    By: /s/ Ian Huen  
      Name: Ian Huen  

     

     

    9

     

    Get the next $APM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APM
    Financials

    Live finance-specific insights

    See more
    • Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

      Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. "Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary transactional and listing documentation. However, current market conditions have introduced significant uncertainty regarding the availability of the required funding for the transaction. After careful consideration, our Board ha

      12/20/24 4:00:00 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

      Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. "During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our ALS-4 and SACT-1 clinical programs and our PathsDx liquid biopsy program through potential collaborations. In light of the macroeconomic environment, we remain vigilant at controlling costs and resources of the company whilst continuing

      12/22/23 4:30:00 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

      ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (NASDAQ:APM, PARIS:APM) and ASP Isotopes Inc. (NASDAQ:ASPI) on The RedChip Money Report® on Bloomberg TV, this Saturday, March 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aptorum Group Limited (NASDAQ:APM): https://www.aptoruminfo.com/interview_accessASP Isotopes Inc. (NASDAQ:ASPI): https://aspiinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years

      3/17/23 8:15:00 AM ET
      $APM
      $ASPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Chemicals
      Industrials

    $APM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

      Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2). The notification does not immediately affect the listing or trading of the company's shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until 14 October 2025, to regain compliance with the continued listing requirements. During this period, Aptorum Group Limited intends to evaluate all available options to restore

      4/16/25 12:27:42 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

      NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the "Ordinary Shares") in a registered direct offering. The ordinary shares are being sold at an offering price of $2.00 per share. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $3.0 million before deducting the placement agent's fees

      1/2/25 10:55:05 AM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

      Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. "Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary transactional and listing documentation. However, current market conditions have introduced significant uncertainty regarding the availability of the required funding for the transaction. After careful consideration, our Board ha

      12/20/24 4:00:00 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APM
    Leadership Updates

    Live Leadership Updates

    See more
    • Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

      Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all Class I directors to hold office until the third annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP as the Company's independent auditors

      12/21/23 4:30:00 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

      Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2022 annual general meeting of shareholders, which was held on December 21, 2022, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all seven directors to hold office until the next annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP (formerly know

      12/22/22 8:00:00 AM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders

      Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced the results of its 2021 annual general meeting of shareholders, which was held on December 2, 2021, in Hong Kong. At the annual general meeting, the required number of shareholders of the Company: Re-elected all of the Company's current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Mr. Charles Bathurst, Dr. Mirko Scherer, Professor Justin Wu and Professor Douglas Arner as directors of the Company until the Company's next annual general meeting o

      12/3/21 8:00:00 AM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APM
    SEC Filings

    See more

    $APM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aptorum Group Limited

      SCHEDULE 13G/A - Aptorum Group Ltd (0001734005) (Subject)

      5/15/25 7:10:38 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Aptorum Group Limited

      20-F - Aptorum Group Ltd (0001734005) (Filer)

      4/30/25 4:34:57 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Aptorum Group Limited

      6-K - Aptorum Group Ltd (0001734005) (Filer)

      4/16/25 4:01:12 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aptorum Group Limited (Amendment)

      SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)

      4/16/24 4:32:40 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aptorum Group Limited (Amendment)

      SC 13G/A - Aptorum Group Ltd (0001734005) (Subject)

      2/2/24 4:02:58 PM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aptorum Group Limited (Amendment)

      SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)

      5/24/23 9:00:21 AM ET
      $APM
      Biotechnology: Pharmaceutical Preparations
      Health Care